Total Payments
$2,161
2024 Payments
$301.82
Companies
16
Transactions
122
Medicare Patients
3,295
Medicare Billing
$324,876
Payment Breakdown by Category
Food & Beverage$2,026 (93.8%)
Education$134.77 (6.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,026 | 119 | 93.8% |
| Education | $134.77 | 3 | 6.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $702.83 | 33 | $0 (2024) |
| ABBVIE INC. | $457.12 | 32 | $0 (2022) |
| Janssen Biotech, Inc. | $217.36 | 8 | $0 (2021) |
| Celgene Corporation | $199.75 | 17 | $0 (2023) |
| PFIZER INC. | $193.04 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $121.46 | 7 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $90.03 | 5 | $0 (2022) |
| Boston Scientific Corporation | $42.02 | 2 | $0 (2018) |
| Amgen Inc. | $28.17 | 1 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $20.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $301.82 | 15 | Gilead Sciences, Inc. ($140.92) |
| 2023 | $159.73 | 8 | PFIZER INC. ($75.09) |
| 2022 | $356.58 | 23 | Celgene Corporation ($158.99) |
| 2021 | $404.76 | 17 | Gilead Sciences, Inc. ($152.52) |
| 2020 | $28.56 | 1 | Gilead Sciences, Inc. ($28.56) |
| 2019 | $90.10 | 6 | AbbVie, Inc. ($37.97) |
| 2018 | $404.13 | 27 | AbbVie, Inc. ($225.42) |
| 2017 | $415.09 | 25 | Gilead Sciences Inc ($205.26) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.28 | General |
| 11/21/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.29 | General |
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.62 | General |
| 09/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.57 | General |
| 09/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.61 | General |
| 06/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.43 | General |
| 06/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/17/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Rare Disease | ||||||
| 06/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/29/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/17/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.12 | General |
| 03/13/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/13/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/23/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/07/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.03 | General |
| Category: Neuroscience | ||||||
| 06/20/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.11 | General |
| 06/14/2023 | PFIZER INC. | XELJANZ (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/24/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $14.82 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.37 | General |
| Category: Neuroscience | ||||||
| 03/02/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.31 | General |
| 12/06/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $11.08 | General |
| Category: Neuroscience | ||||||
| 11/17/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,039 | 1,249 | $457,216 | $111,614 |
| 2022 | 11 | 863 | 1,101 | $361,924 | $88,537 |
| 2021 | 12 | 748 | 1,006 | $320,763 | $74,639 |
| 2020 | 11 | 645 | 981 | $229,553 | $50,085 |
Total Patients
3,295
Total Services
4,337
Medicare Billing
$324,876
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 284 | 284 | $79,236 | $31,703 | 40.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 151 | 209 | $38,038 | $18,810 | 49.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 225 | 225 | $41,175 | $15,103 | 36.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 92 | $15,732 | $9,139 | 58.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 65 | 65 | $104,975 | $7,799 | 7.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 45 | 47 | $15,651 | $6,526 | 41.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 26 | 26 | $47,138 | $4,703 | 10.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 54 | 55 | $65,395 | $4,477 | 6.8% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 57 | 137 | $16,988 | $4,285 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 65 | $7,995 | $3,733 | 46.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 11 | 11 | $4,950 | $2,015 | 40.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $17,563 | $1,994 | 11.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 20 | $2,380 | $1,326 | 55.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 209 | 209 | $58,311 | $23,411 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 174 | $31,668 | $16,665 | 52.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 211 | 211 | $38,613 | $11,629 | 30.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 60 | 60 | $96,900 | $7,664 | 7.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 67 | 195 | $24,180 | $6,222 | 25.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 33 | $10,989 | $5,540 | 50.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 52 | $8,892 | $4,495 | 50.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 62 | 69 | $8,487 | $3,772 | 44.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 18 | 18 | $32,634 | $3,433 | 10.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 37 | 39 | $46,371 | $3,230 | 7.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 41 | $4,879 | $2,475 | 50.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 120 | 120 | $33,480 | $13,079 | 39.1% |
About Dr. Azam Riyaz, MD
Dr. Azam Riyaz, MD is a Gastroenterology healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184613382.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Azam Riyaz, MD has received a total of $2,161 in payments from pharmaceutical and medical device companies, with $301.82 received in 2024. These payments were reported across 122 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,026).
As a Medicare-enrolled provider, Riyaz has provided services to 3,295 Medicare beneficiaries, totaling 4,337 services with total Medicare billing of $324,876. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Torrance, CA
- Active Since 10/19/2005
- Last Updated 09/26/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1184613382
Products in Payments
- Humira (Biological) $221.04
- ZEPOSIA (Drug) $199.75
- STELARA (Biological) $199.26
- XELJANZ (Drug) $139.96
- Creon (Drug) $116.76
- DIFICID (Drug) $109.34
- Vemlidy (Drug) $105.58
- OCALIVA (Drug) $90.03
- INFLECTRA (Biological) $53.08
- MAVYRET (Drug) $52.82
- Mavyret (Drug) $42.52
- GENERAL POLYPECTOMY (Device) $28.86
- AVSOLA (Biological) $28.17
- HUMIRA (Biological) $23.98
- IQIRVO (Drug) $20.00
- SUCRAID (Drug) $19.47
- VOQUEZNA (Drug) $19.15
- REMICADE (Biological) $18.10
- VEGZELMA (Biological) $17.53
- DUPIXENT (Biological) $14.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Torrance
Dr. Tonny Lee, M.d, M.D
Gastroenterology — Payments: $133,902
Gastroenterology $133,902
Sara Kranke
Gastroenterology — Payments: $75,421
Gastroenterology $75,421
Dr. Jennifer Kolb, Md, MD
Gastroenterology — Payments: $60,794
Gastroenterology $60,794
Dr. Jerome Cohen, M.d, M.D
Gastroenterology — Payments: $38,553
Gastroenterology $38,553
Dr. Edward Piken, M.d, M.D
Gastroenterology — Payments: $23,781
Gastroenterology $23,781
Viktor Eysselein, M.d, M.D
Gastroenterology — Payments: $13,509
Gastroenterology $13,509